secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clene Inc. (CLNN)
CIK:        0001822791
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001437749-24-034668
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clene reports Q3 net loss of $8.0M; cash $14.6M; awaits FDA meeting on accelerated ALS approval
--------------------------------------------------------------------------------

- Met with FDA on Nov 1 to discuss accelerated approval pathway for CNM-Au8 in ALS; awaiting meeting minutes.
- Cash, cash equivalents and marketable securities of $14.6M as of Sep 30, 2024, down from $35.0M at Dec 31, 2023.
- Raised $7.3M in October registered direct offering and private placements; runway extended into Q1 2025.
- Amended Avenue debt facility to defer principal payments and extend maturity to Q2 2025.
- Q3 2024 net loss $8.0M ($1.22 per share) vs net loss $2.4M ($0.38 per share) in Q3 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822791/000143774924034668/0001437749-24-034668-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822791/000143774924034668/clnn20240813_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-034668

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer